UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology - Genetic Engineering and Biotechnology News
UCB→Candid Therapeutics
May 6, 2026
Tracking 794 platform M&A deals. Browse platform transactions across all sectors and states.
UCB→Candid Therapeutics
May 6, 2026
Chiron Real Estate
May 6, 2026
Compass→Anywhere
May 5, 2026
NewMark Merrill→Otay Mesa Development Site
May 5, 2026
Cambridge Savings Bank→First Seacoast Bank
May 5, 2026
Greenbelt Capital Partners→Peak Utility Services
May 5, 2026
Quantify Securities Investment Company→Multiple AI companies
May 5, 2026
Enviro Infra Engineers→Suyog Urja
May 5, 2026
Blitzy
May 5, 2026
Expro→Enhanced Drilling
May 5, 2026
KKR→Arctos Partners
May 5, 2026
Expro→Enhanced Drilling
May 5, 2026
Alter Domus→MSC Group
May 5, 2026
IREN→Mirantis
May 5, 2026
VSE→Precision Aviation Group
May 5, 2026
Greenhouse→Ezra AI Labs
May 5, 2026
William Blair→Inner Circle Sports
May 5, 2026
Bullish→Equiniti Group
May 5, 2026
Bullish→Equiniti
May 5, 2026
UPMC→Trinity Health System
May 5, 2026